Patents by Inventor Richard A. Hartz

Richard A. Hartz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
    Patent number: 7205306
    Abstract: Compounds provided herein are novel substituted pyrazinones, pyridines and pyrimidines of Formula (I) and (II): Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: April 17, 2007
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Argyrios G Arvanitis, Paul J Gilligan, Richard A Hartz
  • Pyrimidine derivatives as corticotropin releasing factor inhibitors
    Patent number: 7112585
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: September 26, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Argyrios G. Arvanitis
  • 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
    Patent number: 7098217
    Abstract: 3,7-Dihydro-purine-2,6-dione derivatives of Formula (I) are provided wherein R1, R2, R3 and R4 are herein defined for use as CRF receptor ligands in the treatment of disorders characterized by overexpression of corticotropin releasing factor (CRF), such as anxiety, depression, and irritable bowel syndrome.
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: August 29, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventor: Richard A. Hartz
  • Pyridinyl derivatives for the treatment of depression
    Patent number: 7030145
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: April 18, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Argyrios G. Arvanitis
  • Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
    Patent number: 6894045
    Abstract: Compounds provided herein are novel substituted tetrahydropurinones of Formula (I): wherein R3 is aryl substituted with 0-5 XAr or heteroaryl substituted with 0-4 XhAr. Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: May 17, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Richard A. Hartz
  • 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
    Publication number: 20050026937
    Abstract: Compounds provided herein are 3,7-dihydro-purine-2,6-dione derivatives of Formula (I): Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis or hypoglycemia.
    Type: Application
    Filed: September 8, 2004
    Publication date: February 3, 2005
    Inventor: Richard Hartz
  • Pyrimidine derivatives as corticotropin releasing factor inhibitors
    Publication number: 20040229891
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) 1
    Type: Application
    Filed: March 12, 2004
    Publication date: November 18, 2004
    Inventors: Richard A. Hartz, Argyrios G. Arvanitis
  • Pyridinyl derivatives for the treatment of depression
    Publication number: 20040209917
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) 1
    Type: Application
    Filed: March 12, 2004
    Publication date: October 21, 2004
    Inventors: Richard A. Hartz, Argyrios G. Arvanitis
  • Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
    Publication number: 20030171380
    Abstract: Compounds provided herein are novel substituted pyrazinones, pyridines and pyrimidines of Formula (I) and (II): 1
    Type: Application
    Filed: May 14, 2002
    Publication date: September 11, 2003
    Inventors: Argyrios G. Arvanitis, Paul J. Gilligan, Richard A. Hartz
  • Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
    Publication number: 20030149059
    Abstract: Compounds provided herein are novel substituted tetrahydropurinones of Formula (I): 1
    Type: Application
    Filed: July 10, 2002
    Publication date: August 7, 2003
    Inventor: Richard A. Hartz
  • 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
    Publication number: 20030119831
    Abstract: Compounds provided herein are 3,7-dihydro-purine-2,6-dione derivatives of Formula (I): 1
    Type: Application
    Filed: November 7, 2002
    Publication date: June 26, 2003
    Inventor: Richard A. Hartz